Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Travere Therapeutics, Inc. - Common Stock
(NQ:
TVTX
)
21.41
+0.31 (+1.47%)
Streaming Delayed Price
Updated: 11:45 AM EST, Feb 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Travere Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
November 03, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Report Third Quarter 2023 Financial Results
October 24, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
October 13, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Expert Ratings for Travere Therapeutics
September 22, 2023
Via
Benzinga
Analyst Ratings for Travere Therapeutics
September 06, 2023
Via
Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 11, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shareholder Notice: Investigation over Possible Breaches of Fiduciary Duties
September 29, 2023
San Diego, CA -- (SBWIRE) -- 09/29/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Travere Therapeutics, Inc.
Via
SBWire
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
September 26, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Micron Technology To Rally Around 21%? Here Are 10 Other Analyst Forecasts For Friday
September 22, 2023
Loop Capital increased the price target for Splunk Inc. (NASDAQ: SPLK) from $135 to $157. Loop Capital analyst Yun Kim downgraded the stock from Buy to Hold. Splunk shares fell 0.1% to $144.25 in...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2023
September 22, 2023
Via
Benzinga
Back To Back Trial Failures: Analyst Weighs In On Travere Therapeutics' Prospects, Challenges
September 21, 2023
William Blair downgraded Travere Therapeutics Inc (NASDAQ: TVTX)
Via
Benzinga
Dow Tumbles 200 Points; Darden Restaurants Posts Upbeat Profit
September 21, 2023
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 200 points on Thursday. The Dow traded down 0.58% to 34,239.48 while the NASDAQ fell 1.20% to 13,307.77. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
September 21, 2023
Via
Benzinga
Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
September 21, 2023
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday.
Via
Benzinga
Why Shares of Travere Therapeutics Are Slumping Thursday
September 21, 2023
A mixed trial could hurt a kidney drug's chances of full approval.
Via
The Motley Fool
Why Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-Low
September 21, 2023
It's now up to the FDA whether the company's key drug remains on the market.
Via
Investor's Business Daily
Exposures
Product Safety
Stocks That Hit 52-Week Lows On Thursday
September 21, 2023
During the session on Thursday, 461 stocks hit new 52-week lows.
Via
Benzinga
Gold Down Over 1%; FedEx Shares Rise On Earnings Beat
September 21, 2023
U.S. stocks traded lower midway through trading, with the Dow Jones falling around 150 points on Thursday. The Dow traded down 0.46% to 34,284.15 while the NASDAQ fell 1.05% to 13,327.80. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Nasdaq Down Over 1%; US Initial Jobless Claims Fall More Than Expected
September 21, 2023
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 150 points on Thursday. Following the market opening Thursday, the Dow traded down 0.56% to 34,248.45 while the NASDAQ fell...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Kidney-Disease Focused Travere Therapeutics Stock Trading Lower Today?
September 21, 2023
Travere Therapeutics Inc (NASDAQ: TVTX) announced
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
September 21, 2023
Via
Benzinga
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
September 21, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Broadcom, KB Home And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
September 21, 2023
U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Evercore ISI Group Maintains Outperform Rating for Travere Therapeutics: Here's What You Need To Know
September 19, 2023
Via
Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 11, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: Kidney Care Revolution? How Swedish Biopharma Calliditas Aims To Tackle A Rare Disease With 'Unique, But Pretty Simple' Drug
September 08, 2023
Calliditas, a rare disease company focused on kidney ailments, is optimistic of its lead drug taking off in a big way.
Via
Benzinga
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
September 05, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
September 05, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
August 31, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
August 24, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.